SCHEMBL3342166

SCHEMBL3342166

CCOC(=O)c1cnc(-c2cccc(F)c2)cc1Oc1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.47
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
MAPT P10636 5/20 0.45
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP1A2 P05177 5/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
GRM7 Q14831 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.42
HTT P42858 2/20 0.42
MAPK1 P28482 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3343855 0.92 MAPT (0.44) CSNK1DJAK2JAK3MAPTALDH1A1
SCHEMBL3341299 0.91 ALDH1A1 (0.47) MAPTALDH1A1NPSR1CYP1A2CYP2C9
SCHEMBL3344993 0.90 CYP1A2 (0.52) JAK2JAK3MAPTALDH1A1NPSR1
SCHEMBL3342554 0.88 TP53 (0.44) MAPTALDH1A1NPSR1CYP1A2CYP2C9
SCHEMBL3344387 0.85 MAPT (0.54) MAPTALDH1A1NPSR1CYP1A2CYP2C9
SCHEMBL3347331 0.85 KMO (0.46) HTTTP53
SCHEMBL3341133 0.85 JAK2 (0.53) CSNK1DJAK2JAK3MAPTALDH1A1
SCHEMBL3340782 0.82 ALDH1A1 (0.49) JAK2JAK3MAPTALDH1A1NPSR1
SCHEMBL3341626 0.81 MAPT (0.48) MAPTALDH1A1NPSR1CYP1A2CYP2C9
SCHEMBL1956268 0.80 TSHR (0.47) MAPTALDH1A1NPSR1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
WO-2008031500-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS PPARA, PPARD, PPARG CSNK1D 3748/4885JAK2 1106/4885JAK3 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.